Pancreato-biliary cancers, mainly pancreatic cancer and extrahepatic cholangiocarcinoma, are almost uniformly fatal malignancies with increasing incidence and poor prognosis even when diagnosed in the early stages of the disease.

This activity focuses entirely on issues related to the Organs at Risk (OAR) in the setting of thoracic radiation. Discussion centers on protecting the OARs and managing acute and late toxicities. Each speaker focuses on a different clinical situation.

Conventionally fractionated external beam radiation therapy (EBRT) has a long-standing track record of safety and excellent treatment outcomes in the management of all prostate cancer risk groups.

Unfavorable intermediate-risk prostate cancer is commonly encountered in clinical practice but there is relatively little data focusing on treatment outcomes specific and limited to this patient cohort, with most clinical trials grouping these patients with favorable intermediate-risk disease or

The role of this activity reviews growing indications for radiation therapy for liver cancer, educates providers on radiation therapy options (SBRT, particle therapy) and the potential impact of hepatic reserve capacity on decision making, explores challenges and opportunities for clinical trials